Jarden remains neutral on AFT Pharmaceuticals

Jarden remains neutral on AFT Pharmaceuticals
AFT has launched 22 new products across seven therapeutic areas and has 61 countries selling its Maxigesic products. (Image: AFT)
Ella Somers
Jarden won’t budge on its neutral rating for AFT Pharmaceuticals – even after the multinational pharmaceutical firm reported record revenue and declared a maiden dividend.AFT announced on Monday that its operating revenue was up 20% to $156.6 million for the 12 months to March 31, while operating profit from product sales and royalties rose 38% to $18.8m.Net profit after tax was $10.7m, down from the $19.8m in the same period a year ago. The core Australasian business contributed the most to growth, with revenue increasing 23.5%.&nb...